Table 3 Median score and prevalence by ICS dose group for ICQ total and 15 domains
From: A self-rating scale for patient-perceived side effects of inhaled corticosteroids
ICQ Domain | Non ICS Inhaler n = 27 | % >0 | Low dose ICS n = 61 | % >0 | Mid dose ICS n = 62 | % >0 | High dose ICS n = 105 | % >0 | p-value†|
|---|---|---|---|---|---|---|---|---|---|
Total Score | 5 (1–11) | [89] | 7 (3–14) | [92] | 10 (3–21) | [92] | 15 (9–30) | [97] | <0.001 |
Voice Problems | 2 (0–8) | [56] | 3 (0–13) | [70] | 6 (0–22) | [63] | 13 (3–34) | [79] | <0.001 |
Oropharynx Problems | 11 (0–19) | [67] | 9 (1–28) | [75] | 18 (3–41) | [81] | 20 (6–44) | [86] | 0.003 |
Unpleasant Taste | 7 (0–24) | [67] | 5 (0–20) | [61] | 5 (0–19) | [68] | 10 (2–29) | [77] | 0.012 |
Skin, Hair and Nails | 0 (0–14) | [41] | 5 (0–19) | [57] | 14 (0–24) | [69] | 19 (5–37) | [81] | <0.001 |
Mood Problems | 0 (0–0) | [11] | 0 (0–19) | [33] | 0 (0–33) | [46] | 11 (0–39) | [59] | <0.001 |
Taste Disruption | 0 (0–0) | [11] | 0 (0–0) | [23] | 0 (0–0) | [16] | 0 (0–14) | [39] | 0.001 |
Perspiration | 0 (0–25) | [30] | 0 (0–33) | [45] | 0 (0–38) | [46] | 17 (0–42) | [64] | 0.002 |
Oropharyngeal Itching | 0 (0–0) | [15] | 0 (0–8) | [27] | 0 (0–8) | [32] | 0 (0–25) | [41] | 0.002 |
Thirst | 0 (0–25) | [48] | 8 (0–25) | [55] | 8 (0–35) | [58] | 25 (0–50) | [72] | <0.001 |
Tiredness | 0 (0–13) | [36] | 8 (0–25) | [51] | 8 (0–33) | [57] | 25 (0–42) | [74] | <0.001 |
Oral Candidiasis | 0 (0–0) | [7] | 0 (0–0) | [8] | 0 (0–0) | [8] | 0 (0–0) | [20] | 0.014 |
Facial Oedema | 0 (0–0) | [7] | 0 (0–0) | [7] | 0 (0–0) | [13] | 0 (0–0) | [22] | 0.005 |
Vision Deterioration | 0 (0–0) | [19] | 0 (0–17) | [31] | 0 (0–17) | [33] | 0 (0–33) | [38] | 0.066 |
Dental Deterioration | 0 (0–0) | [11] | 0 (0–0) | [15] | 0 (0–13) | [25] | 0 (0–33) | [40] | <0.001 |
Eye Dryness | 0 (0–17) | [26] | 0 (0–17) | [28] | 0 (0–17) | [31] | 0 (0–50) | [50] | 0.001 |